Abstract
Recent annotation of the human transcriptome revealed that only 2 % of the genome encodes proteins while the majority of human genome is transcribed into noncoding RNAs. Although we are just beginning to understand the diverse roles long noncoding RNAs (lncRNAs) play in molecular and cellular processes, they have potentially important roles in human development and pathophysiology. However, targeting of RNA by traditional structure-based design of small molecule inhibitors has been difficult, due to a lack of understanding of the dynamic tertiary structures most RNA molecules adopt. Antisense oligonucleotides (ASOs) are capable of targeting specific genes or transcripts directly through Watson–Crick base pairing and thus can be designed based on sequence information alone. These agents have made possible specific targeting of “non-druggable targets” including RNA molecules. Here we describe how ASOs can be applied in preclinical studies to reduce levels of lncRNAs of interest.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Rask-Andersen M, Almen MS, Schioth HB (2011) Trends in the exploitation of novel drug targets. Nat Rev Drug Discov 10:579–590
Overington JP, Al-Lazikani B, Hopkins AL (2006) How many drug targets are there? Nat Rev Drug Discov 5:993–996
Bennett CF, Swayze EE (2010) RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 50:259–293
Yamamoto Y, Loriot Y, Beraldi E, Zhang F, Wyatt AW, Al Nakouzi N et al (2015) Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide resistant prostate cancer cell growth. Clin Cancer Res 21:1675–1687
Lam MT, Cho H, Lesch HP, Gosselin D, Heinz S, Tanaka-Oishi Y et al (2013) Rev-Erbs repress macrophage gene expression by inhibiting enhancer-directed transcription. Nature 498:511–515
Meng L, Ward AJ, Chun S, Bennett CF, Beaudet al, Rigo F (2014) Towards a therapy for Angelman syndrome by targeting a long non-coding RNA. Nature 518(7539):409–12
Wheeler TM, Leger AJ, Pandey SK, MacLeod AR, Nakamori M, Cheng SH et al (2012) Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 488:111–115
Sauvageau M, Goff LA, Lodato S, Bonev B, Groff AF, Gerhardinger C et al (2013) Multiple knockout mouse models reveal lincRNAs are required for life and brain development. ELife 2:e01749
Li L, Chang HY (2014) Physiological roles of long noncoding RNAs: insight from knockout mice. Trends Cell Biol 24:594–602
Wapinski O, Chang HY (2011) Long noncoding RNAs and human disease. Trends Cell Biol 21:354–361
Li X, Wu Z, Fu X, Han W (2014) lncRNAs: insights into their function and mechanics in underlying disorders. Mutat Res Rev Mutat Res 762:1–21
Meister G (2013) Argonaute proteins: functional insights and emerging roles. Nat Rev Genet 14:447–459
Cerritelli SM, Frolova EG, Feng C, Grinberg A, Love PE, Crouch RJ (2003) Failure to produce mitochondrial DNA results in embryonic lethality in RNaseh1 null mice. Mol Cell 11:807–815
Wu H, Lima WF, Zhang H, Fan A, Sun H, Crooke ST (2004) Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J Biol Chem 279:17181–17189
Lee RG, Crosby J, Baker BF, Graham MJ, Crooke RM (2013) Antisense technology: an emerging platform for cardiovascular disease therapeutics. J Cardiovasc Transl Res 6:969–980
Buller HR, Bethune C, Bhanot S, Gailani D, Monia BP, Raskob GE et al (2015) Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med 372:232–240
Gaudet D, Brisson D, Tremblay K, Alexander VJ, Singleton W, Hughes SG et al (2014) Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med 371:2200–2206
Rigo F, Seth PP, Bennett CF (2014) Antisense oligonucleotide-based therapies for diseases caused by pre-mRNA processing defects. Adv Exp Med Biol 825:303–352
Rigo F, Chun SJ, Norris DA, Hung G, Lee S, Matson J et al (2014) Pharmacology of a central nervous system delivered 2′-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates. J Pharmacol Exp Ther 350:46–55
Vickers TA, Wyatt JR, Burckin T, Bennett CF, Freier SM (2001) Fully modified 2′ MOE oligonucleotides redirect polyadenylation. Nucleic Acids Res 29:1293–1299
Baek MS, Yu RZ, Gaus H, Grundy JS, Geary RS (2010) In vitro metabolic stabilities and metabolism of 2′-O-(methoxyethyl) partially modified phosphorothioate antisense oligonucleotides in preincubated rat or human whole liver homogenates. Oligonucleotides 20:309–316
Henry SP, Geary RS, Yu R, Levin AA (2001) Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors? Current Opin Investig Drugs 2:1444–1449
Monia BP, Lesnik EA, Gonzalez C, Lima WF, McGee D, Guinosso CJ et al (1993) Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem 268:14514–14522
Prakash TP (2011) An overview of sugar-modified oligonucleotides for antisense therapeutics. Chem Biodivers 8:1616–1641
Geary RS, Watanabe TA, Truong L, Freier S, Lesnik EA, Sioufi NB et al (2001) Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J Pharmacol Exp Ther 296:890–897
Lee RG, Fu W, Graham MJ, Mullick AE, Sipe D, Gattis D et al (2013) Comparison of the pharmacological profiles of murine antisense oligonucleotides targeting apolipoprotein B and microsomal triglyceride transfer protein. J Lipid Res 54:602–614
Seth PP, Vasquez G, Allerson CA, Berdeja A, Gaus H, Kinberger GA et al (2010) Synthesis and biophysical evaluation of 2′,4′-constrained 2′O-methoxyethyl and 2′,4′-constrained 2′O-ethyl nucleic acid analogues. J Org Chem 75:1569–1581
Hong DS, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Zhou T, Schmidt J, Jo M, LeeSJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MVP, Mohseni M, Lawson D, Reimer C, Blakey DC, Xiao X, Hsu J, Monia BP, and MacLeod AR (2015). AZD9150, a nextgeneration antisense oligonucleotide Inhibitor of STAT3, with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med (in press)
Senn JJ, Burel S, Henry SP (2005) Non-CpG-containing antisense 2′-methoxyethyl oligonucleotides activate a proinflammatory response independent of Toll-like receptor 9 or myeloid differentiation factor 88. J Pharmacol Exp Ther 314:972–979
Lima WF, Vickers TA, Nichols J, Li C, Crooke ST (2014) Defining the factors that contribute to on-target specificity of antisense oligonucleotides. PLoS One 9:e101752
Gutschner T, Hammerle M, Eissmann M, Hsu J, Kim Y, Hung G et al (2013) The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res 73:1180–1189
Hung G, Xiao X, Peralta R, Bhattacharjee G, Murray S, Norris D et al (2013) Characterization of target mRNA reduction through in situ RNA hybridization in multiple organ systems following systemic antisense treatment in animals. Nucleic Acid Ther 23:369–378
Vickers TA, Freier SM, Bui HH, Watt A, Crooke ST (2014) Targeting of repeated sequences unique to a gene results in significant increases in antisense oligonucleotide potency. PLoS One 9:e110615
Skotte NH, Southwell AL, Ostergaard ME, Carroll JB, Warby SC, Doty CN et al (2014) Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients. PLoS One 9:e107434
Ostergaard ME, Southwell AL, Kordasiewicz H, Watt AT, Skotte NH, Doty CN et al (2013) Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. Nucleic Acids Res 41:9634–9650
Castro D, Iannaccone ST (2014) Spinal muscular atrophy: therapeutic strategies. Curr Treat Options Neurol 16:316
Ward AJ, Norrbom M, Chun S, Bennett CF, Rigo F (2014) Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotides. Nucleic Acids Res 42:5871–5879
Cavaluzzi MJ, Borer PN (2004) Revised UV extinction coefficients for nucleoside-5′-monophosphates and unpaired DNA and RNA. Nucleic Acids Res 32:e13
Koller E, Vincent TM, Chappell A, De S, Manoharan M, Bennett CF (2011) Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res 39:4795–4807
Yu RZ, Grundy JS, Geary RS (2013) Clinical pharmacokinetics of second generation antisense oligonucleotides. Expert Opin Drug Metab Toxicol 9:169–182
Yu RZ, Lemonidis KM, Graham MJ, Matson JE, Crooke RM, Tribble DL et al (2009) Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochem Pharmacol 77:910–919
Acknowledgements
We thank XueHai Liang for discussion and sharing unpublished data. We are grateful to Lauren Elder for editorial assistance.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Zhou, T., Kim, Y., MacLeod, A.R. (2016). Targeting Long Noncoding RNA with Antisense Oligonucleotide Technology as Cancer Therapeutics. In: Feng, Y., Zhang, L. (eds) Long Non-Coding RNAs. Methods in Molecular Biology, vol 1402. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3378-5_16
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3378-5_16
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3376-1
Online ISBN: 978-1-4939-3378-5
eBook Packages: Springer Protocols